Axcella Health Stock (NASDAQ:AXLA)


ForecastOwnershipChart

Previous Close

$NaN

52W Range

$0.36 - $4.58

50D Avg

-

200D Avg

-

Market Cap

-

Avg Vol (3M)

-

Beta

0.57

Div Yield

-

AXLA Company Profile


Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

11

IPO Date

May 09, 2019

Website

AXLA Performance


Latest Earnings Call Transcripts


Q3 22Nov 01, 22 | 11:54 AM
Q4 21Mar 30, 22 | 12:24 PM
Q2 21Jul 31, 21 | 3:08 PM

Peer Comparison


TickerCompany
MGTADianthus Therapeutics, Inc.
NUVBNuvation Bio Inc.
ARDSAridis Pharmaceuticals, Inc.
CFRXContraFect Corporation
ADILAdial Pharmaceuticals, Inc.
HSTOHistogen Inc.
KTTAPasithea Therapeutics Corp.
CTMXCytomX Therapeutics, Inc.
AKTXAkari Therapeutics, Plc
ASMBAssembly Biosciences, Inc.
CYCNCyclerion Therapeutics, Inc.
RNXTRenovoRx, Inc.
SLRXSalarius Pharmaceuticals, Inc.
NLTXNeurogene Inc.
KZRKezar Life Sciences, Inc.
TILInstil Bio, Inc.